Simone Villa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Simone Villa has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Luigi Ruffo Codecasa
TB and NTM Regional Reference Clinic, Villa Marelli, ASST Grande Ospedale Metropolitano Niguarda, 20159 Milan, Italy
7 shared publications Maurizio Ferrarese
Regional TB Reference Centre, Villa Marelli Institute and Laboratory/ASST Niguarda, Milan, Italy
6 shared publicationsMarino Faccini
Health Protection Agency of the Metropolitan Area of Milan, Milan, Italy
5 shared publications- Mario Carlo Raviglione
Università degli Studi di Milano
5 shared publications Sabrina Senatore
Health Protection Agency of the Metropolitan Area of Milan, Milan, Italy
5 shared publicationsAnna Lamberti
Health Protection Agency, Metropolitan Area of Milan, Milan, Italy
4 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Springer Nature in BMC Public Health
Mapping the COVID-19 epidemic in Lombardy, Italy, years 2020–2022: a population-based study of temporal trends, geographic distribution, and risk factors for incidence, hospitalization, and mortality
Background: In late winter of 2020, the first locally transmitted outbreak of COVID-19 in Europe was reported in Lombardy, Italy. This study provides a comprehensive analysis of the epidemic’s trajectory in this heavily impacted region from March 2020 to the end of 2022. Methods: We conducted a cohort study utilizing anonymized data from Lombardy’s eight local public health authorities (LPHAs). The dataset included all individuals registered with the Regional Health Service as of January 2020, with monthly data aggregated by sex, age, country of origin, municipality or ZIP area, and comorbidities. SARS-CoV-2 lineage data from the regional repository allowed us to segment the study period into four sub-periods by predominant viral lineages. We report the temporal trends and geographical distribution of three outcomes (COVID-19 incidence, hospital admissions, and mortality) as well as COVID-19 test positivity rates and vaccination coverage across LPHAs and Local Health Districts (LHDs). Multivariable regression models were employed to identify key risk factors for COVID-19 incidence and mortality in each of the four sub-periods. Results: We describe the impact of the COVID-19 pandemic in a population of over 10 million people, of whom 45% were aged ≥ 50 years and 22% had a history of cardiac diseases. The outbreak was concentrated, in the early phases, in a few LHDs, none of which had large cities. As soon as the SARS-CoV-2 transmission increased in the population, hospital admissions and mortality decreased over time, especially for areas impacted early. Our results confirm the role of age and neurologic and renal comorbidities, as well as geographical location, hinting at the impact of local epidemic dynamics and health system factors on both outcomes. Conclusions: Our findings provide essential insights into the dynamics of COVID-19 in one of Europe’s earliest and most severely affected regions, contributing valuable evidence to the global understanding of pandemic management and public health responses.
- 2 October 2026
- Published by Springer Nature in BMC Public Health
Open AccessMapping the COVID-19 epidemic in Lombardy, Italy, years 2020–2022: a population-based study of temporal trends, geographic distribution, and risk factors for incidence, hospitalization, and mortality
Background: In late winter of 2020, the first locally transmitted outbreak of COVID-19 in Europe was reported in Lombardy, Italy. This study provides a comprehensive analysis of the epidemic’s trajectory in this heavily impacted region from March 2020 to the end of 2022. Methods: We conducted a cohort study utilizing anonymized data from Lombardy’s eight local public health authorities (LPHAs). The dataset included all individuals registered with the Regional Health Service as of January 2020, with monthly data aggregated by sex, age, country of origin, municipality or ZIP area, and comorbidities. SARS-CoV-2 lineage data from the regional repository allowed us to segment the study period into four sub-periods by predominant viral lineages. We report the temporal trends and geographical distribution of three outcomes (COVID-19 incidence, hospital admissions, and mortality) as well as COVID-19 test positivity rates and vaccination coverage across LPHAs and Local Health Districts (LHDs). Multivariable regression models were employed to identify key risk factors for COVID-19 incidence and mortality in each of the four sub-periods. Results: We describe the impact of the COVID-19 pandemic in a population of over 10 million people, of whom 45% were aged ≥ 50 years and 22% had a history of cardiac diseases. The outbreak was concentrated, in the early phases, in a few LHDs, none of which had large cities. As soon as the SARS-CoV-2 transmission increased in the population, hospital admissions and mortality decreased over time, especially for areas impacted early. Our results confirm the role of age and neurologic and renal comorbidities, as well as geographical location, hinting at the impact of local epidemic dynamics and health system factors on both outcomes. Conclusions: Our findings provide essential insights into the dynamics of COVID-19 in one of Europe’s earliest and most severely affected regions, contributing valuable evidence to the global understanding of pandemic management and public health responses.
- Top Cited PapersOpen Access
- 1 January 2026
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 32 (1) , 45-54
Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024–25
Reduced Hospitalizations after RSV Immunization
- 1 January 2026
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 32 (1) , 45-54
Top Cited PapersOpen AccessReduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024–25
Reduced Hospitalizations after RSV Immunization
- Open Access
- 25 September 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (38) , 2500659
Letter to the editor: Towards effective implementation of hospital-onset bacteraemia and fungaemia as a quality metric
Eurosurveillance.org is the online home of Eurosurveillance, Europe's journal on infectious disease surveillance, epidemiology, prevention and control.
- 25 September 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (38) , 2500659
Open AccessLetter to the editor: Towards effective implementation of hospital-onset bacteraemia and fungaemia as a quality metric
Eurosurveillance.org is the online home of Eurosurveillance, Europe's journal on infectious disease surveillance, epidemiology, prevention and control.
- Open Access
- 22 May 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (20) , 2500315
From multiple measles genotype D8 introductions in 2024 to sustained B3 local transmission in and around Milan, northern Italy, January to April 2025
An outbreak of measles virus genotype B3 is ongoing in Milan and surrounding areas since February 2025, with 27 cases identified in 32 laboratory-confirmed measles cases. Most cases were locally acquired and young adults. Phylogenetic analysis indicated the presence of a unique lineage closely related to strains circulating in Morocco. The lack of epidemiological links between several affected individuals suggests case numbers are being underestimated. The continuous transmission raises concerns about the potential re-establishment of endemic circulation in northern Italy.
- 22 May 2025
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 30 (20) , 2500315
Open AccessFrom multiple measles genotype D8 introductions in 2024 to sustained B3 local transmission in and around Milan, northern Italy, January to April 2025
An outbreak of measles virus genotype B3 is ongoing in Milan and surrounding areas since February 2025, with 27 cases identified in 32 laboratory-confirmed measles cases. Most cases were locally acquired and young adults. Phylogenetic analysis indicated the presence of a unique lineage closely related to strains circulating in Morocco. The lack of epidemiological links between several affected individuals suggests case numbers are being underestimated. The continuous transmission raises concerns about the potential re-establishment of endemic circulation in northern Italy.
- Open Access
- 1 May 2025
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 31 (5) , 1057-1059
Increased Pneumonia-Related Emergency Department Visits, Northern Italy
Increased Pneumonia-Related Emergency Department Visits, Northern Italy
- 1 May 2025
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 31 (5) , 1057-1059
Open AccessIncreased Pneumonia-Related Emergency Department Visits, Northern Italy
Increased Pneumonia-Related Emergency Department Visits, Northern Italy
- Open Access
- 22 January 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (2) , 236
Wastewater Surveillance for SARS-CoV-2 in Northern Italy: An Evaluation of Three Different Gene Targets
Wastewater-based epidemiology has emerged as a complementary tool for the monitoring of COVID-19 pandemic waves and for the circulation of viral variants. The selection, standardization, and dynamics of different SARS-CoV-2 RNA targets in wastewater requires further investigation. In the present study, 106 wastewater samples were collected over a 24-month period from the wastewater treatment plant of Sondrio, north Italy, and were analyzed for the presence of SARS-CoV-2 RNA through the quantification of ORF1b, N1, and N3 gene targets via one-step real-time qPCR. In general, the three RNA targets demonstrated different performances and dynamics over the studied time period, underlying the usefulness of multiple viral targets in the surveillance of SARS-CoV-2 in wastewater. During the first 12 months, the quantification of the selected SARS-CoV-2 viral targets also correlated with the reported clinical cases in the same geographical area; however, from the overall data analysis this did not appear to significantly anticipate the epidemic waves. In conclusion, this study further supports the use of wastewater surveillance as a real time indicator of the human circulation of SARS-CoV-2. Moreover, the use of multiple viral gene targets has been shown to improve the reliability of SARS-CoV-2 surveillance in wastewater over time.
- 22 January 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (2) , 236
Open AccessWastewater Surveillance for SARS-CoV-2 in Northern Italy: An Evaluation of Three Different Gene Targets
Wastewater-based epidemiology has emerged as a complementary tool for the monitoring of COVID-19 pandemic waves and for the circulation of viral variants. The selection, standardization, and dynamics of different SARS-CoV-2 RNA targets in wastewater requires further investigation. In the present study, 106 wastewater samples were collected over a 24-month period from the wastewater treatment plant of Sondrio, north Italy, and were analyzed for the presence of SARS-CoV-2 RNA through the quantification of ORF1b, N1, and N3 gene targets via one-step real-time qPCR. In general, the three RNA targets demonstrated different performances and dynamics over the studied time period, underlying the usefulness of multiple viral targets in the surveillance of SARS-CoV-2 in wastewater. During the first 12 months, the quantification of the selected SARS-CoV-2 viral targets also correlated with the reported clinical cases in the same geographical area; however, from the overall data analysis this did not appear to significantly anticipate the epidemic waves. In conclusion, this study further supports the use of wastewater surveillance as a real time indicator of the human circulation of SARS-CoV-2. Moreover, the use of multiple viral gene targets has been shown to improve the reliability of SARS-CoV-2 surveillance in wastewater over time.
- Open Access
- 22 April 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (4) , e014630
Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis
Background Research and development (R&D) of new drugs and regimens against tuberculosis (TB) is evolving to meet new challenges and face limited investments in the sector. To effectively improve and fill existing gaps, researchers and trialists should engage a broad spectrum of stakeholders. With this study, we aim to map the interests in TB R&D raised by the main stakeholders in the TB field. Methods We conducted semistructured, short interviews to gather insight and viewpoints on innovation on TB drugs and regimens R&D of policy-makers, national TB programme officers, donors, funders, non-governmental organisations and research institutions. A composite measure of the relevance of topics that emerged was computed by implementing different models considering the importance for researchers and the urgency to implement those changes during the trial, the number of citations each topic received, and the maximum value of the influence of stakeholders who had raised the topic. Results 50 stakeholders, out of 56 identified, were interviewed and almost half were policy-makers and governmental institutions. Several stakeholders highlighted the importance of disseminating information about clinical trials’ methodology and emerging preliminary results, followed by the need to pursue early discussion around access and pricing of safe and effective TB innovations, although different categories of stakeholders prioritised different topics. Using different methods for ranking topics, the results remained almost unchanged. Notably, post-trial operational research ranked higher in models with higher weight for the parameter considering the number of citations. Conclusion Researchers and research consortia embarking on phase 2 and 3 clinical trials should consider a broad set of elements when planning and designing trials’ protocols, all aiming at lowering the price and improving access to emerging TB innovations, besides meeting regulatory criteria. This can only be achieved by consulting and engaging relevant stakeholders in the discussion.
- 22 April 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (4) , e014630
Open AccessTowards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis
Background Research and development (R&D) of new drugs and regimens against tuberculosis (TB) is evolving to meet new challenges and face limited investments in the sector. To effectively improve and fill existing gaps, researchers and trialists should engage a broad spectrum of stakeholders. With this study, we aim to map the interests in TB R&D raised by the main stakeholders in the TB field. Methods We conducted semistructured, short interviews to gather insight and viewpoints on innovation on TB drugs and regimens R&D of policy-makers, national TB programme officers, donors, funders, non-governmental organisations and research institutions. A composite measure of the relevance of topics that emerged was computed by implementing different models considering the importance for researchers and the urgency to implement those changes during the trial, the number of citations each topic received, and the maximum value of the influence of stakeholders who had raised the topic. Results 50 stakeholders, out of 56 identified, were interviewed and almost half were policy-makers and governmental institutions. Several stakeholders highlighted the importance of disseminating information about clinical trials’ methodology and emerging preliminary results, followed by the need to pursue early discussion around access and pricing of safe and effective TB innovations, although different categories of stakeholders prioritised different topics. Using different methods for ranking topics, the results remained almost unchanged. Notably, post-trial operational research ranked higher in models with higher weight for the parameter considering the number of citations. Conclusion Researchers and research consortia embarking on phase 2 and 3 clinical trials should consider a broad set of elements when planning and designing trials’ protocols, all aiming at lowering the price and improving access to emerging TB innovations, besides meeting regulatory criteria. This can only be achieved by consulting and engaging relevant stakeholders in the discussion.
- Open Access
- 1 January 2024
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 39 (Supplement) , i93-i106
Leveraging global investments for polio eradication to strengthen health systems’ resilience through transition
Since the launch of the Global Polio Eradication Initiative in 1988, more than US$20 billion has been invested globally in polio eradication. The World Health Organization and its partners are currently supporting Member States to transition the functions used to eradicate polio to strengthen their health systems. This study analyses global polio activities through the lens of health systems and the Common Goods for Health (CGH). Polio activities include key health system functions such as surveillance and response systems and immunization, which are essential to maintaining resilient health systems. They also support essential functions such as policy development, planning, training and capacity building, which are often underfunded in many countries. To improve overall resilience, it is critical to continue to integrate these functions into local health systems so that the capacity built through the polio eradication programme can be used for broader public health purposes. It is vital that this integration process be tailored to each country’s unique health system context, rather than using a one-size-fits-all approach. While integration of all polio activities into local health systems is ideal, the transition to domestic financing may be coordinated with other global health financing mechanisms. This would reduce funding fragmentation and transaction costs, and allow for a focus on health system functions as a whole rather than just disease-specific efforts. The transition to domestic financing of polio activities could be staggered, prioritizing the transition to domestic funding for activities with limited global externalities, while seeking longer-term external funding for those that are global CGH.
- 1 January 2024
- Published by Oxford University Press (OUP) in Health Policy and Planning
- Vol. 39 (Supplement) , i93-i106
Open AccessLeveraging global investments for polio eradication to strengthen health systems’ resilience through transition
Since the launch of the Global Polio Eradication Initiative in 1988, more than US$20 billion has been invested globally in polio eradication. The World Health Organization and its partners are currently supporting Member States to transition the functions used to eradicate polio to strengthen their health systems. This study analyses global polio activities through the lens of health systems and the Common Goods for Health (CGH). Polio activities include key health system functions such as surveillance and response systems and immunization, which are essential to maintaining resilient health systems. They also support essential functions such as policy development, planning, training and capacity building, which are often underfunded in many countries. To improve overall resilience, it is critical to continue to integrate these functions into local health systems so that the capacity built through the polio eradication programme can be used for broader public health purposes. It is vital that this integration process be tailored to each country’s unique health system context, rather than using a one-size-fits-all approach. While integration of all polio activities into local health systems is ideal, the transition to domestic financing may be coordinated with other global health financing mechanisms. This would reduce funding fragmentation and transaction costs, and allow for a focus on health system functions as a whole rather than just disease-specific efforts. The transition to domestic financing of polio activities could be staggered, prioritizing the transition to domestic funding for activities with limited global externalities, while seeking longer-term external funding for those that are global CGH.
- 8 September 2023
- Published by Springer Nature
- p. 81-85
Tuberculosis